Alterations in energy balance following exenatide administration.
about
Hypothalamic Obesity in Craniopharyngioma Patients: Disturbed Energy Homeostasis Related to Extent of Hypothalamic Damage and Its Implication for Obesity InterventionPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseEffects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adultsGLP-1 based therapeutics: simultaneously combating T2DM and obesity.Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targetsGLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese MiceMice Deficient in Proglucagon-Derived Peptides Exhibit Glucose Intolerance on a High-Fat Diet but Are Resistant to Obesity.Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-DiabetesThe role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.GLP-1: benefits beyond pancreas.Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.Does endogenous GLP-1 affect resting energy expenditure and fuel selection in overweight and obese adults?Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet
P2860
Q26786921-94738421-551C-42A6-848C-5E7BC293CF35Q27027920-1E6EB8E6-6760-41BF-BA4C-5631E86B493FQ33737073-4D832606-D694-4F6F-8059-1BB4AA8C994AQ35200252-2E7F31EB-D70C-4935-8EDE-AA1A6B71B615Q35668745-AD2CD8A1-8621-41F8-A776-348B8C5DFB2CQ35769544-21535234-5E38-4156-92A7-918C5DDC4736Q35778163-9CF99DD7-F40C-41C6-AE44-D37A77552EC9Q35860311-58708E22-2D4A-4B08-B4F1-8D4182779439Q36072493-7A9E189A-8AF5-4042-B830-1FD5C3AEF585Q38101677-1168D9DD-1883-4042-8D36-D92129B6F646Q38238288-8BABCD52-CAB9-488A-8A2A-D1BF0B4F49F9Q38753804-36333A4C-EE9A-454C-A9AD-D3BB0528C8B8Q47197056-9668F9B8-DF32-4FFE-9ED0-F6B72A6AAC55Q47252691-91B2A55E-DC73-467D-915F-7CCC6F5D6232Q48190910-4F516BC7-395B-421D-A2C1-DD304099C476Q57591304-E9AC3FC3-14CF-4134-AB0E-AF370571C82A
P2860
Alterations in energy balance following exenatide administration.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Alterations in energy balance following exenatide administration.
@ast
Alterations in energy balance following exenatide administration.
@en
type
label
Alterations in energy balance following exenatide administration.
@ast
Alterations in energy balance following exenatide administration.
@en
prefLabel
Alterations in energy balance following exenatide administration.
@ast
Alterations in energy balance following exenatide administration.
@en
P2093
P2860
P356
P1476
Alterations in energy balance following exenatide administration.
@en
P2093
Dale A Schoeller
Melissa Meredith
Natalie Racine
Roger Kulstad
Yoram Shenker
P2860
P304
P356
10.1139/H2012-068
P577
2012-06-26T00:00:00Z